Outlook Therapeutics Management

Management criteria checks 3/4

Outlook Therapeutics' CEO is Russ Trenary, appointed in Jul 2021, has a tenure of 2.75 years. total yearly compensation is $1.76M, comprised of 34.1% salary and 65.9% bonuses, including company stock and options. directly owns 0.7% of the company’s shares, worth $1.29M. The average tenure of the management team and the board of directors is 2.5 years and 4.8 years respectively.

Key information

Russ Trenary

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage	34.1%
CEO tenure	2.8yrs
CEO ownership	0.7%
Management average tenure	2.5yrs
Board average tenure	4.8yrs

Recent management updates

Recent updates

Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt In A Risky Way?

Nov 03

Outlook Therapeutics resubmits application for eye disease wAMD drug, shares rise 8%

Aug 30

Outlook Therapeutics GAAP EPS of -$0.08 misses by $0.01

Aug 10

Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt?

Jul 06

Outlook Therapeutics announces full cash pre-payment of convertible promissory note

Jul 05

CEO Compensation Analysis

How has Russ Trenary's remuneration changed compared to Outlook Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-US$51m
Sep 30 2023	US$2m	US$600k	-US$59m
Jun 30 2023	n/a	n/a	-US$60m
Mar 31 2023	n/a	n/a	-US$57m
Dec 31 2022	n/a	n/a	-US$70m
Sep 30 2022	US$1m	US$600k	-US$66m
Jun 30 2022	n/a	n/a	-US$65m
Mar 31 2022	n/a	n/a	-US$60m
Dec 31 2021	n/a	n/a	-US$53m
Sep 30 2021	US$8m	US$145k	-US$53m

Compensation vs Market: Russ's total compensation ($USD1.76M) is about average for companies of similar size in the US market ($USD1.60M).

Compensation vs Earnings: Russ's compensation has increased whilst the company is unprofitable.

CEO

Russ Trenary (65 yo)

2.8yrs

Tenure

US$1,758,862

Compensation

Mr. C. Russell Trenary, III, also known as Russ, serves as a President, Chief Executive Officer and Director at Outlook Therapeutics, Inc., since July 06, 2021. He served as the Chief Executive Officer and...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ralph Thurman	Independent Executive Chairman	6yrs	US$242.50k	0.0027% $ 4.9k
C. Trenary	President	2.8yrs	US$1.76m	0.70% $ 1.3m
Lawrence Kenyon	Executive VP	8.6yrs	no data	0.0042% $ 7.7k
Jeffrey Evanson	Chief Commercial Officer	5.4yrs	US$718.20k	0.18% $ 331.1k
Alicia Tozier	Senior Vice President	2.1yrs	no data	no data
Joel Prieve	Senior Vice President of Licensing and M&A	2.2yrs	no data	no data
Surendra Sharma	Senior Vice President of Medical Affairs	1.3yrs	no data	no data
Jennifer Kissner	Senior Vice President of Clinical Development & Regulatory Affairs	no data	no data	no data
Jedd Comiskey	Senior VP - Head of Europe	less than a year	no data	no data

2.5yrs

Average Tenure

61yo

Average Age

Experienced Management: OTLK's management team is considered experienced (2.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Ralph Thurman	Independent Executive Chairman	6yrs	US$242.50k	0.0027% $ 4.9k
C. Trenary	President	2.8yrs	US$1.76m	0.70% $ 1.3m
Lawrence Kenyon	Executive VP	5.7yrs	no data	0.0042% $ 7.7k
Kurt Hilzinger	Independent Director	8.3yrs	US$95.00k	0.11% $ 193.7k
Julia Haller	Independent Director	1.7yrs	US$79.00k	0% $ 0
Julian Gangolli	Independent Non-Employee Director	4yrs	US$112.50k	0% $ 0
Arun Pillai	Board Observer	no data	no data	no data
Gerd Auffarth	Independent Non-Employee Director	4yrs	US$79.00k	0% $ 0
Faisal Sukhtian	Independent Director	6.6yrs	US$113.00k	0.015% $ 27.9k
Yezan Haddadin	Independent Director	6.5yrs	US$110.00k	0.023% $ 41.3k
Andong Huang	Independent Director	3.8yrs	US$75.00k	0% $ 0

4.8yrs

Average Tenure

62yo

Average Age

Experienced Board: OTLK's board of directors are considered experienced (4.8 years average tenure).

Outlook Therapeutics Management

Management criteria checks 3/4

Key information

Recent management updates

Outlook Therapeutics, Inc., Annual General Meeting, Mar 07, 2024

Outlook Therapeutics, Inc. Appoints Jedd Comiskey as Senior VP – Head of Europe

Outlook Therapeutics, Inc., Annual General Meeting, Mar 29, 2023

High number of new directors

Chief Commercial Officer recently sold US$204k worth of stock

Outlook Therapeutics, Inc. Announces Executive Appointments

Recent updates

Outlook Therapeutics, Inc. announced that it has received $5.000002 million in funding from Syntone Ventures LLC

Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD

Price target decreased by 13% to US$38.50

Outlook Therapeutics, Inc. announced that it has received $59.999961 million in funding from a group of investors

New major risk - Share price stability

Outlook Therapeutics Announces Effective Date for 1-For-20 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

New minor risk - Market cap size

Price target decreased by 11% to US$2.01

No longer forecast to breakeven

Outlook Therapeutics, Inc., Annual General Meeting, Mar 07, 2024

Outlook Therapeutics, Inc. Doses First Subject in Norse Eight

Outlook Therapeutics Receives FDA Agreement under Special Protocol Assessment for 90 Day Non-Inferiority Study, NORSE EIGHT

Outlook Therapeutics, Inc. announced that it expects to receive $65 million in funding from a group of investors

Forecast breakeven date pushed back to 2026

Outlook Therapeutics, Inc. Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010

Outlook Therapeutics, Inc. Announces Strategic Organizational Realignment

Consensus revenue estimates decrease by 92%, EPS upgraded

Outlook Therapeutics, Inc. Appoints Jedd Comiskey as Senior VP – Head of Europe

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Pomerantz Law Firm Announces the Filing of A Class Action Against Outlook Therapeutics, Inc. and Certain Officers

Outlook Therapeutics Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates decrease by 33%

Price target decreased by 61% to US$2.63

Outlook Therapeutics, Inc. Provides Regulatory Update on FDA Review of ONS-5010 / LYTENAVA (bevacizumab-vikg) for the Treatment of Wet AMD

Consensus EPS estimates fall by 12%

New major risk - Negative shareholders equity

Consensus EPS estimates upgraded to US$0.21 loss

Outlook Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $16.927904 million.

Price target decreased by 7.3% to US$6.13

Forecast breakeven date moved forward to 2024

Forecast breakeven date pushed back to 2025

Outlook Therapeutics, Inc., Annual General Meeting, Mar 29, 2023

Price target decreased by 9.5% to US$6.33

High number of new directors

Chief Commercial Officer recently sold US$204k worth of stock

Outlook Therapeutics, Inc. Announces Executive Appointments

Consensus forecasts updated

Forecast breakeven date moved forward to 2024

Outlook Therapeutics, Inc. announced that it expects to receive $30 million in funding from Streeterville Capital, LLC

Outlook Therapeutics, Inc. Announces Validation of Marketing Authorization Application by the European Medicines Agency for ONS-5010 as a Treatment for Wet AMD

Forecast breakeven date pushed back to 2025

Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt In A Risky Way?

Outlook Therapeutics, Inc. Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Independent Director recently bought US$111k worth of stock

Price target increased to US$7.25

No longer forecast to breakeven

Outlook Therapeutics, Inc Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Outlook Therapeutics resubmits application for eye disease wAMD drug, shares rise 8%

Price target decreased to US$6.33

Outlook Therapeutics, Inc. Announces Appointment of Julia A. Haller as Board of Director

Outlook Therapeutics GAAP EPS of -$0.08 misses by $0.01

Is Outlook Therapeutics (NASDAQ:OTLK) Using Too Much Debt?

Outlook Therapeutics announces full cash pre-payment of convertible promissory note

Outlook Therapeutics, Inc. Confirms Status of Biologics License Application Submission for ONS-5010

Outlook Therapeutics: A One-Buck Lottery Ticket

Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as A Treatment for Wet AMD

Price target decreased to US$6.58

Outlook Therapeutics, Inc Submits Biologics License Application to the U.S. Food and Drug Administration for ONS-5010 as a Treatment for Wet AMD

Is Outlook Therapeutics (NASDAQ:OTLK) Using Debt Sensibly?

Outlook Therapeutics, Inc. Appoints Alicia Tozier as Senior Vice President of Marketing and Market Access

Independent Director recently bought US$257k worth of stock

Outlook Therapeutics, Inc. Announces Appointment of Joel Prieve as Senior Vice President, Commercial Operations

Outlook Therapeutics, Inc., Annual General Meeting, Mar 23, 2022

Outlook Therapeutics, Inc., Annual General Meeting, Mar 23, 2022

Outlook Therapeutics: Likely FDA Approval, Possible Buyout

Outlook Therapeutics, Inc. to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina Symposia

Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial

Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010/LYTENAVA™

Consensus forecasts updated